Systemic Antifungal Therapy for Invasive Pulmonary Infections

Ronen Ben-Ami

doi:10.3390/jof9020144

journal article Open Access Jan 21, 2023

Systemic Antifungal Therapy for Invasive Pulmonary Infections

Ronen Ben-Ami

Journal of Fungi Vol. 9 No. 2 pp. 144 · MDPI AG

View at Publisher Save 10.3390/jof9020144

Abstract

Antifungal therapy for pulmonary fungal diseases is in a state of flux. Amphotericin B, the time-honored standard of care for many years, has been replaced by agents demonstrating superior efficacy and safety, including extended-spectrum triazoles and liposomal amphotericin B. Voriconazole, which became the treatment of choice for most pulmonary mold diseases, has been compared with posaconazole and itraconazole, both of which have shown clinical efficacy similar to that of voriconazole, with fewer adverse events. With the worldwide expansion of azole-resistant Aspergillus fumigatus and infections with intrinsically resistant non-Aspergillus molds, the need for newer antifungals with novel mechanisms of action becomes ever more pressing.

Topics

No keywords indexed for this article. Browse by subject →

References

172

[1]

Bongomin, F., Gago, S., Oladele, R.O., and Denning, D.W. (2017). Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision. J. Fungi, 3. 10.3390/jof3040057

[2]

Webb "Epidemiology and Clinical Features of Invasive Fungal Infection in a US Health Care Network" Open Forum Infect. Dis. (2018) 10.1093/ofid/ofy187

[3]

Nnadi, N.E., and Carter, D.A. (2021). Climate change and the emergence of fungal pathogens. PLoS Pathog., 17. 10.1371/journal.ppat.1009503

[4]

Ashraf "Re-drawing the Maps for Endemic Mycoses" Mycopathologia (2020) 10.1007/s11046-020-00431-2

[5]

Nett "Antifungal Agents: Spectrum of Activity, Pharmacology, and Clinical Indications" Infect. Dis. Clin. N. Am. (2016) 10.1016/j.idc.2015.10.012

[6]

Herbrecht "Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis" N. Engl. J. Med. (2002) 10.1056/nejmoa020191

[7]

Patterson "Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America" Clin. Infect. Dis. (2016) 10.1093/cid/ciw326

[8]

Ullmann "Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline" Clin. Microbiol. Infect. (2018) 10.1016/j.cmi.2018.01.002

[9]

Tissot "ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients" Haematologica (2017) 10.3324/haematol.2016.152900

[10]

Maertens "Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: A phase 3, randomised, controlled, non-inferiority trial" Lancet (2021) 10.1016/s0140-6736(21)00219-1

[11]

Maertens "Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial" Lancet (2016) 10.1016/s0140-6736(15)01159-9

[12]

Arendrup "Prospective Multicenter International Surveillance of Azole Resistance in Aspergillus fumigatus" Emerg. Infect. Dis. (2015) 10.3201/eid2106.140717

[13]

Snelders, E., van der Lee, H.A., Kuijpers, J., Rijs, A.J., Varga, J., Samson, R.A., Mellado, E., Donders, A.R., Melchers, W.J., and Verweij, P.E. (2008). Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med., 5. 10.4016/8254.01

[14]

Cornelia "Changes in the epidemiological landscape of invasive mould infections and disease" J. Antimicrob. Chemother. (2017) 10.1093/jac/dkx028

[15]

Lionakis "Breakthrough Invasive Mold Infections in the Hematology Patient: Current Concepts and Future Directions" Clin. Infect. Dis. (2018)

[16]

Hoenigl "The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin" Drugs (2021) 10.1007/s40265-021-01611-0

[17]

Antifungal Pharmacokinetics and Pharmacodynamics

A. J. Lepak, D. R. Andes

Cold Spring Harbor Perspectives in Medicine 2014 10.1101/cshperspect.a019653

[18]

Lewis "Pharmacodynamic implications for use of antifungal agents" Curr. Opin. Pharmacol. (2007) 10.1016/j.coph.2007.05.004

[19]

Verheggen "Management of drug–drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs" Lancet Haematol. (2022) 10.1016/s2352-3026(21)00232-5

[20]

Bruggemann "Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents" Clin. Infect. Dis. (2009) 10.1086/598327

[21]

Thorpe "Effect of oral antacid administration on the pharmacokinetics of oral fluconazole" Antimicrob. Agents Chemother. (1990) 10.1128/aac.34.10.2032

[22]

Zimmermann "Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole" Eur. J. Clin. Pharmacol. (1994) 10.1007/bf00199879

[23]

Cousin "Dosing guidelines for fluconazole in patients with renal failure" Nephrol. Dial. Transplant. (2003) 10.1093/ndt/gfg363

[24]

Pappas "Alopecia associated with fluconazole therapy" Ann. Intern. Med. (1995) 10.7326/0003-4819-123-5-199509010-00006

[25]

John "Therapeutic drug monitoring of systemic antifungal agents: A pragmatic approach for adult and pediatric patients" Expert Opin. Drug Metab. Toxicol. (2019) 10.1080/17425255.2019.1671971

[26]

2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis

John N. Galgiani, Neil M. Ampel, Janis E. Blair et al.

Clinical Infectious Diseases 2016 10.1093/cid/ciw360

[27]

Ampel "Factors and outcomes associated with the decision to treat primary pulmonary coccidioidomycosis" Clin. Infect. Dis. (2009) 10.1086/595687

[28]

Blair "Characteristics of patients with mild to moderate primary pulmonary coccidioidomycosis" Emerg. Infect. Dis. (2014) 10.3201/eid2006.131842

[29]

Galgiani "Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group" Ann. Intern. Med. (2000) 10.7326/0003-4819-133-9-200011070-00009

[30]

Food and Drug Administration (2023, January 18). Sporanox (Itraconazole). Full Prescribing Information, Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020083s040s041s044lbl.pdf.

[31]

Hostetler "Effect of cyclodextrin on the pharmacology of antifungal oral azoles" Antimicrob. Agents Chemother. (1992) 10.1128/aac.36.2.477

[32]

Heykants "The clinical pharmacokinetics of itraconazole: An overview" Mycoses (1989) 10.1111/j.1439-0507.1989.tb02296.x

[33]

Arendrup "How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST)" Clin. Microbiol. Infect. (2020) 10.1016/j.cmi.2020.06.007

[34]

Tverdek "Antifungal agents and liver toxicity: A complex interaction" Expert Rev. Anti-Infect. Ther. (2016) 10.1080/14787210.2016.1199272

[35]

Wang "Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection" Antimicrob. Agents Chemother. (2010) 10.1128/aac.01657-09

[36]

Marr "Cyclophosphamide metabolism is affected by azole antifungals" Blood (2004) 10.1182/blood-2003-07-2512

[37]

Sharkey "High-dose itraconazole in the treatment of severe mycoses" Antimicrob. Agents Chemother. (1991) 10.1128/aac.35.4.707

[38]

Hoffmann "Itraconazole induced hypertension and hypokalemia: Mechanistic evaluation" Mycoses (2018) 10.1111/myc.12749

[39]

Teaford "The Many Faces of Itraconazole Cardiac Toxicity" Mayo Clin. Proc. Innov. Qual Outcomes (2020) 10.1016/j.mayocpiqo.2020.05.006

[40]

Stevens "A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis" N. Engl. J. Med. (2000) 10.1056/nejm200003163421102

[41]

Cauwenbergh "The treatment of aspergillosis and aspergilloma with itraconazole, clinical results of an open international study (1982-1987)" Mycoses (1988) 10.1111/j.1439-0507.1988.tb03653.x

[42]

Agarwal "Itraconazole in chronic cavitary pulmonary aspergillosis: A randomised controlled trial and systematic review of literature" Mycoses (2013) 10.1111/myc.12075

[43]

Stevens "Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria" Arch. Intern. Med. (1997) 10.1001/archinte.1997.00440370097010

[44]

Wheat "Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America" Clin. Infect. Dis. (2007) 10.1086/521259

[45]

Chapman "Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America" Clin. Infect. Dis. (2008) 10.1086/588300

[46]

Dismukes "Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group" Am. J. Med. (1992) 10.1016/0002-9343(92)90575-v

[47]

Food and Drug Administration (2023, January 18). Vfend (Voriconazole). Full Prescribing Information, Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021266s032lbl.pdf.

[48]

Manavathu "Organism-dependent fungicidal activities of azoles" Antimicrob. Agents Chemother. (1998) 10.1128/aac.42.11.3018

[49]

Purkins "Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens" Antimicrob. Agents Chemother. (2002) 10.1128/aac.46.8.2546-2553.2002

[50]

Walsh "Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children" Pediatr. Infect. Dis. J. (2002) 10.1097/00006454-200203000-00015

Showing 50 of 172 references

Cited By

18

Successful treatment of pulmonary mucormycosis caused by Rhizopus arrhizus in a diabetic patient with combined bronchoscopic local and systemic antifungal therapy: A case report and literature review

Dongling Kou, Liqun He · 2026

Diagnostic Microbiology and Infecti...

Successful Treatment of Post-tuberculosis Pulmonary Aspergillosis With Liposomal Amphotericin B in a Patient After a Rare Event of Voriconazole-Associated Hypotension: A Case Report

Ali Alsaeed · 2025

Cureus

A global perspective of the changing epidemiology of invasive fungal disease and real-world experience with the use of isavuconazole

George R. Thompson, Sharon C-A Chen · 2024

Medical Mycology